Back

Myocardial and metabolic effects of intermittent levosimendan in advanced heart failure

11 May 2026 (09:37 - 10:45)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - pharmacotherapy (5) Pharmacotherapy Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Raquel Fernandes Da Silva

ACES Alentejo Central, Evora (Portugal)

7 More presentations in this session

Presentation thumbnail
Trend of echocardiographic parameters, ventricular-arterial coupling and biomarkers in advanced heart failure outpatients undergoing intermittent therapy with levosimendan
Doctor G. Togni (Bergamo, IT)
Abstract Slides
Presentation thumbnail
Echocardiographic and biomarker response to levosimendan cycles in advanced heart failure
Doctor R. Fernandes Da Silva (Evora, PT)
Abstract Slides
Presentation thumbnail
Real-world effectiveness of inclisiran in heart failure patients with coronary artery disease across the ejection fraction spectrum
Doctor A. Cerar (Ljubljana, SI)
Abstract Slides
Presentation thumbnail
Meldonium improves aerobic capability and quality of life in HFpEF patients
Professor K. Trusinskis (Riga, LV)
Abstract Slides
Presentation thumbnail
Managing mavacamten drug interactions in obstructive hypertrophic cardiomyopathy: the role of a clinical pharmacist in a multidisciplinary team
Ms E. Lozo (Zagreb, HR)
Abstract Slides

Access the full session

Session thumbnail
ePosters in chronic heart failure - pharmacotherapy (5)

The Event

Event poster

Heart Failure 2026

11 May 2026 09:37 CET
You may be interested in
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios
thumbnail
Congress Presentation
Audience Q&A
thumbnail
Congress Session
Meet the Experts: summation of the science - treatment of chronic heart failure in 2023

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources